I find Stuart Roberts opinion interesting, but only as an opinion.
He does write many many words .. and there is some meaning in there.
On previous reports for other companies & the blog he had been writing -- I felt he doesn't have great handle on probability of success. Those numbers seem made up to allow a specific per-share valuation.
I wonder if there is too long spent talking to the company & doesn't have a bunch of researchers, clinicians, and hospital buyers to refer to. From such external insights you are more likely to get a good sense of the true risks for any biotech.
updated ballieu report - target range 25-55c, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.00 |
Change
0.200(4.17%) |
Mkt cap ! $77.52M | |||
| Open | High | Low | Value | Volume |
| $4.85 | $5.14 | $4.85 | $28.00K | 5.692K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1567 | $4.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.08 | 525 | 1 |
View Market Depth
| Last trade - 15.02pm 18/07/2025 (20 minute delay) ? |
| AVR (ASX) Chart |